Chemotherapy of metastatic seminoma
1985

Chemotherapy for Metastatic Seminoma

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): J. Schuette, N. Niederle, M.E. Scheulen, S. Seeber, C.G. Schmidt

Primary Institution: Innere Universitdtsklinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen, FRG.

Hypothesis

The study investigates the efficacy and toxicity of different combination chemotherapies in treating advanced disseminated seminomas.

Conclusion

The study suggests a high probability of continuous complete remission in patients with bulky retroperitoneal and widespread metastatic seminoma.

Supporting Evidence

  • 89% of patients achieved complete remission after treatment.
  • 82% of patients are free of disease after a median follow-up of 28 months.
  • Significant myelosuppression was observed in previously irradiated patients.

Takeaway

Doctors treated 28 men with a type of testicular cancer using different medicines, and most of them got better.

Methodology

Retrospective analysis of treatment response and survival in patients with metastatic seminoma.

Limitations

The study is retrospective and includes a limited number of patients.

Participant Demographics

Median age was 41 years, with a range of 23-52 years; 50% had elevated human chorionic gonadotropin levels.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication